Archive
Filter
Jazz is up almost 30% since my February 2017 recommendation. Recent commentary from the FDA regarding branded companies thwarting new generic entrants may drag the stock down. I'll look for a better entry point to re-visit this name. Read More
Both the Walmart and Abbvie options trades worked out well for subscribers. A bit more on how these trade suggestions should work and what's on the calendar moving forward. Carbonite continues to deliver good news and why Air Transport Services lumbers along. Read More
Sell to close the June 15, 2018 call on Abbvie (NYSE: ABBV) with a strike price of $105 at $4.20 or higher for a swift 50% gain. Symbol (ABBV180615C105). It’s a beautiful thing when an options trade suggestion works out almost exactly as planned. Abbvie boosted investor confidence regarding… Read More
Sell Celgene as the stock has closed below its $83 stop loss limit for two consecutive days. Despite decent news, the stock continues to drop. Read More
Walmart is selling off due to its super pricey entry into the Indian market. Book this significant gain in the June puts. Read More
Harsco's surge in demand began even before the government's policy changes on aluminum and steel and what Abbvie's Dutch tender means for investors. Read More
Buy Abbvie ahead of a May 9th conference when investors will hear more about its recent surprising success in its new Hep C drug. Read More
Old Dominion Freight and SAIA, both less than truckload shippers, saw earnings rise on higher rates and increased volume of shipments. Investors, nervous about the sustainability of the global economy sold the stocks off a bit, unjustifiably, I believe. PRA redeemed itself with a strong backlog and more. Read More